Hepatology Elsewhere

You have full text access to this OnlineOpen article

Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical†

  1. Ravi K. Ghanta M.D.,
  2. Kevin D. Mullen M.D.

Article first published online: 25 OCT 2005

DOI: 10.1002/hep.20946

Issue

Hepatology

Hepatology

Volume 42, Issue 5, pages 1206–1207, November 2005

Additional Information

How to Cite

Ghanta, R. K., Mullen, K. D. (2005), Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical. Hepatology, 42: 1206–1207. doi: 10.1002/hep.20946

Author Information

  1. Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve School of Medicine, Cleveland, OH

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 25 OCT 2005
  2. Article first published online: 25 OCT 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (60K)

References

  • 1
    Uribe M, Moran S, Poo JL, Mendez-Sanchez L, Guevara L, Garcia-Ramos G. Beneficial effect of carbohydrate maldigestion induced by disaccharidase inhibitor (AO-128) in the treatment of chronic portal systemic encephalopathy. Scan J Gastroenterol 1998; 33: 1099–1106.
  • 2
    Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. HEPATOLOGY 2002; 35: 716–721.
    Direct Link:
  • 3
    Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol 2001; 96: 1968–1976.
    Direct Link:
  • 4
    Sanaka MR, Ong JP, Mullen KD. Challenges of designing hepatic encephalopathy treatment trials. HEPATOLOGY 2003: 38; 527–528.
    Direct Link:
View Full Article (HTML) Get PDF (60K)